27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Bethesda, MD, June 10, 2015 (GLOBE NEWSWIRE) -- IGC, Inc. (NYSE-MKT: IGC) announces the third vertical in itseffort to gain a leading position in the emerging legal cannabisindustry. Our strategy is to develop a product portfolio ofphytocannabinoid-based therapies for the treatment of a wide rangeof therapeutic indications including pain, epilepsy, and otherniche severe terminal diagnosis, which are life altering or lifethreatening.
Most recently, the company applied for a provisional patentbased on a novel therapy that uses cannabinoid extracts for thetreatment of seizures in dogs and cats. The therapy, which isexpected to also have applications in humans, is administered usinga variety of delivery technologies. We expect to establishmetabolic profiling and apply to the FDA for trials.
To facilitate the development of the product portfolio, IGC isentering into partnerships with a range of organizations that canprovide cost effective solutions for metabolic profiling, clinicaltrials, and regulatory approvals that in most cases will benecessary to eventually commercialize our products.
"The Company is also continuing to assemble an internationalnetwork of doctors, veterinarians, and researchers with extensiveexpertise in various indications, medicines containing controlledsubstances, plant-based products, extraction technologies, and drugdelivery technologies. In addition, we have assembled expertsin patent law, clinical trials, and regulatory procedures," saidRam Mukunda, IGC's CEO.
Mukunda added, "Among our senior advisors is Dr. Ranga Krishnawho founded International Pharma Trials ("IPT"), a company withover 150 employees that assists a number of U.S. pharmaceuticalcompanies in performing clinical trials. IPT has a specialtyin pain and epilepsy. Dr. Krishna himself is a neurologistwith a sub-specialty in epilepsy surgery."
"Jack Lynch who has over 50 years of experience in practicebefore US District and Appellate courts and the US Patent andTrademark Office is another of our key senior advisors leading ourintellectual property filing strategy and was instrumental in thisfiling as well as other filings, which we will be disclosing,"Mukunda continued.
To help our shareholders and potential investors betterunderstand our direction, we have deployed a new website atwww.igcinc.usthat explains bothour current electronics business and our expansion into thephytocannabinoid business as well as our strategy and the synergiesbetween these businesses. The website also providesbackground on phytocannabinoids and why they hold hope for variousailments. We have also restarted our presence on social media:twitter (@IGCIR)," said Mukunda.
Our launch of the pharmaceutical unit is part of IGC'spreviously articulated efforts to drive shareholder value bybuilding three segments within the legal cannabis sector: a)facilities and technologies, b) legal cannabis research andinvestment banking, and c) pharmaceuticals based onphytocannabinoids.
About IGC
Based in Bethesda, Maryland, IGC, Inc. is takingdefensible, high growth, high margin positions in two of theworld's fastest growing industries electronics and cannabis. Our involvement in the electronics and cannabis industriescreates unique synergies and advantages that we believe will behighly profitable in the short and long term. Ourwebsite: www.igcinc.us. Followus on twitter (@IGCIR).
Forward-looking Statements:
Some of the statements contained in this pressrelease that are not historical facts constitute forward- lookingstatements under the federal securities laws. Forward-lookingstatements can be identified by the use of the words "may," "will,""should," "could," "expects," "plans," "anticipates," "believes,""estimates," "predicts," "intends," "potential," "proposed" or thenegative of those terms. The term "crowd funding" or "crowdfunding"is not a recognized regulatory term and is meant as a reference toofferings of investment securities under the JOBS Act of 2012 forregulations both currently adopted and to be adopted in the futureby the Securities & Exchange Commission and FINRA as a resultof that legislation. These statements are not a guarantee of futuredevelopments and are subject to risks, uncertainties and otherfactors, some of which are beyond IGC's control and are difficultto predict. Consequently, actual results may differ materially frominformation contained in the forward-looking statements as a resultof future changes or developments in our business, our acquisitionand diversification strategy, our competitive environment,infrastructure demands, iron ore availability and governmental,regulatory, political, economic, legal and social conditions in,among other places, China and India. Except as required by federalsecurities laws, IGC undertakes no obligation to publicly updateany forward- looking statements, whether as a result of newinformation, future events, or otherwise. Other factors and risksthat could cause or contribute to actual results differingmaterially from such forward- looking statements have beendiscussed in greater detail in IGC's Form 10- K for fiscal yearended March 31, 2014, and in subsequent reports filed with the U.S.SEC.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!